Serina Therapeutics shares jump 27.78% intraday on anticipation of Q2 2026 SER-252 safety data and second financing tranche.

Serina Therapeutics surged 27.78% intraday amid anticipation of key clinical and financial developments. The stock movement coincided with news that the biopharmaceutical company is nearing a critical juncture in its Parkinson’s candidate, SER-252, with initial safety data from its Phase 1b trial expected in Q2 2026. Investors are also closely watching the planned closing of a second financing tranche by the end of April 2026, which is expected to support ongoing trials and extend the company’s operational runway. Positive market sentiment reflects optimism around the drug’s clinical potential and the company's ability to secure necessary funding, both of which are seen as crucial to de-risking the development path and validating its proprietary drug delivery platform.